|
- IRMS - Nicolae Testemitanu SUMPh
- 1. COLECȚIA INSTITUȚIONALĂ
- MedEspera: International Medical Congress for Students and Young Doctors
- MedEspera 2012
Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12710/19653
Title: | Change of C-reactive protein and tumor necrosis factor-a levels in Diabetes Mellitus type 2 and L-arginine-L-glutamate |
Authors: | Shved, M. Chernukhina, O. Mazur, L. |
Keywords: | C-reactive protein;tumor necrosis factor-a;Diabetes Mellitus;L-arginine-L-glutamate |
Issue Date: | 2012 |
Publisher: | State Medical and Pharmaceutical University Nicolae Testemitanu, Medical Students and Residents Association, Scientific Association of Students and Young Doctors |
Citation: | SHVED, M., CHERNUKHINA, O., MAZUR, L. Change of C-reactive protein and tumor necrosis factor-a levels in Diabetes Mellitus type 2 and L-arginine-L-glutamate. In: MedEspera: the 4th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2012, p. 11. |
Abstract: | The Purpose of our study was to determine C-reactive protein (CRP) and tumor necrosis factor- a
(TNF-a) levels in patients with nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes mellitus and
their correction with NO synthesis precursor L-arginine-L-glutamate.
Materials and methods: We examined 30 patients with type 2 diabetes aged 35 to 65, who had symptoms of NAFLD. The functional state of liver, changes in plasma levels of pro-inflammatory cytokine
TNF-a and CRP were evaluated in patients treated with L-arginine-L-glutamate.
Results: It was determined that in patients with type 2 diabetes and NAFLD the levels of TNF-a
and CRP were significantly higher than in patients with type 2 diabetes and healthy subjects. A statistically significant decrease of TNF-a and CRP levels was established 8-10 days after the beginning of
administration of L-arginine-L-glutamate in patients with type 2 diabetes and NAFLD as compared to
the control group (patients with type 2 diabetes who did not take L-arginine-L-glutamate). The treatment was followed by improvement of functional liver tests (bilirubin, general cholesterol, triglycerides,
(3-lipoproteins, alaninaminotransferase, and general protein) and liver ultrasound picture.
Conclusions: Thus, administration of the NO-synthesis precursor L-arginine-L-glutamate in patients
with diabetes mellitus type 2 and NAFLD contributes to the decrease of systemic inflammation, in particular - C-reactive protein and tumor necrosis factor- a and improvement of functional liver tests. |
metadata.dc.relation.ispartof: | MedEspera: The 4th International Medical Congress for Students and Young Doctors, May 17-19, 2012, Chisinau, Republic of Moldova |
URI: | http://repository.usmf.md/handle/20.500.12710/19653 |
Appears in Collections: | MedEspera 2012
|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
|